Biomarker Panel for Dendritic Cell Subset Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers to distinguish between effector and tolerogenic dendritic cell subsets in patients undergoing allergen immunotherapy, making it difficult to assess the orientation of immune responses and monitor treatment efficacy.
Innovation Solution
Identification of novel biomarkers such as STAB1 and C1Q, which are used to determine the expression levels in peripheral blood mononuclear cells (PBMCs) to differentiate between regulatory and effector T cell responses, allowing for the assessment of immunotherapy response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to assess immune response orientation, then treatment monitoring is performed, but accurate differentiation between effector and tolerogenic dendritic cell subsets is not achieved
Solution Approach 1:
The patent uses differential expression patterns of specific biomarkers (C1Q, STAB1, MMP9, CD86, HLA-DR) as molecular 'color codes' to distinguish between effector and tolerogenic dendritic cell subsets. Each subset has a characteristic biomarker profile that serves as an identifier, enabling accurate classification and assessment of immune response orientation through biomarker expression analysis.
2Reliability
If no specific biomarkers are used, then general immune response assessment is performed, but prediction of treatment responders is not achieved
Solution Approach 1:
The patent segments the complex immune response assessment into distinct biomarker categories: early predictors (C1Q, STAB1), maturation markers (HLA-DR, CD86), and functional markers (MMP9). This segmentation allows the complex system to be analyzed through multiple independent biomarker dimensions, improving prediction reliability while maintaining manageable analytical complexity through focused measurement of specific marker panels.
3Measurement precision
If detailed biomarker analysis is performed, then accurate immune response orientation is identified, but treatment monitoring complexity increases
Solution Approach 1:
The patent establishes a universal biomarker panel (C1Q, STAB1, MMP9, CD86, HLA-DR) that serves multiple functions: predicting treatment response, determining immune response orientation (effector vs. tolerogenic), and monitoring treatment progression. This multi-functional biomarker system simplifies treatment monitoring by providing a single comprehensive analytical approach that addresses multiple assessment needs simultaneously.
Data Source
Figure 1
Figure 2A
Figure 2B~2E
AI summary
The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.